Prodigiosin isolated from cell wall of Serratia marcescens alters expression of apoptosis-related genes and increases apoptosis in colorectal cancer cells

Medical Oncology

Volumn 32, Issue 1, 2015, Pages 1-8

  Hassankhani, Ramin ^a   Sam, Mohammad Reza ^b,c   Esmaeilou, Mohammad ^a   Ahangar, Prinaz ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b URMIA UNIVERSITY   (Iran)

^c Royan Stem Cell Technology Company West Azarbaijan Cord Blood Bank   (Iran)

Author keywords

Apoptosis; Apoptotic related genes; Caspase 3; Colorectal cancer; Prodigiosin; Survivin

Indexed keywords

CASPASE 3; MESSENGER RNA; PRODIGIOSIN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; SURVIVIN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL COUNT; CELL DEATH; CELL ISOLATION; CELL PROLIFERATION; CELL VIABILITY; CELL WALL; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HT 29 CELL LINE; HUMAN; HUMAN CELL; SERRATIA MARCESCENS; TUMOR GENE; ADENOCARCINOMA; CELL SURVIVAL; COLORECTAL TUMOR; DRUG EFFECTS; FLOW CYTOMETRY; PATHOLOGY; POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; FLOW CYTOMETRY; HT29 CELLS; HUMANS; POLYMERASE CHAIN REACTION; PRODIGIOSIN; SERRATIA MARCESCENS;

EID: 84920181310     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0366-0     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.
2. Safaee A, Fatemi SR, Ashtari S, Vahedi M, Moghimi-Dehkordi B, Zali MR. Four years incidence rate of colorectal cancer in Iran: a survey of national cancer registry data-implications for screening. Asian Pac J Cancer Prev. 2012;13:2695–8.
3. Deorukhkar AA, Chander R, Ghosh SB, Sainis KB. Identification of a red-pigmented bacterium producing a potent anti-tumor N-alkylated prodigiosin as Serratia marcescens. Res Microbiol. 2007;158:399–404.
4. Sumathi C, MohanaPriya D, Swarnalatha S, Dinesh, GM, Sekaran G. Production of prodigiosin using tannery fleshing and evaluating its pharmacological effects. Sci World J. 2014;2014:1–8.
5. Francisco R, Pérez-Tomás R, Gimènez-Bonafé P, Soto-Cerrato V, Giménez-Xavier P, Ambrosio S. Mechanisms of prodigiosin cytotoxicity in human neuroblastoma cell lines. Eur J Pharmacol. 2007;572:111–9.
6. Ho TF, Peng YT, Chuang SM, Lin SC, Feng BL, Lu CH, Yu WJ, Chang JS, Chang CC. Prodigiosin down-regulates survivin to facilitate paclitaxel sensitization in human breast carcinoma cell lines. Toxicol Appl Pharm. 2009;235:253–60.
7. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut. 2000;46:645–50.
8. Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, Lacorte JM, Staedel C, Lesuffleur T. Resistance of colon cancer cells to long-terms 5-flourouracil exposure is correlated to the relative level of BCL-2 and BCL-XL in addition to BAX and P53 status. Int J Cancer. 2002;98:498–504.
9. Koehler BC, Scherr AL, Lorenz S, Urbanik T, Kautz N, Elssner C, Welte S, Bermejo JL, Jäger D, Schulze-Bergkamen H. Beyond cell death—antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro. PLoS One. 2013;8:1–12.
10. Srobel T, Swanson L, Korsmeyer S, Cannistra SA. BAX enhances paclitaxel-induced apoptosis trough a p53-independent pathway. Proc Natl Acad Sci. 1996;93:14094–9.
11. Lee JW, Soung YH, Kim SY. Inactivating mutations of proapoptotic Bad gene in human colon cancers. Carcinogenesis. 2004;25:1371–6.
12. Montaner B, Navarro S, Piqué M, Vilaseca M, Martinell M, Giralt E, Gil J, Pérez-Tomás R. Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in hematopoietic cancer cell lines. Br J Pharmacol. 2000;131:585–93.
13. Montaner B, Perez-Tomas R. Prodigiosin-induced apoptosis in human colon cancer cells. Life Sci. 2001;68:2025–36.
14. Díaz-Ruiz C, Montaner B, Pérez-Tomás R. Prodigiosin induces cell death and morphological changes indicative of apoptosis in gastric cancer cell line HGT-1. Histol Histopathol. 2001;16:415–21.
15. Pocard M, Chevillard S, Villaudy J, Poupon MF, Dutrillaux B, Remvikos Y. Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation. Oncogene. 1996;12:875–82.
16. Royds JA, Iacopetta B. p53 and disease: when the guardian angel fails. Cell Death Differ. 2006;13:1017–26.
17. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46–54.
18. Li F, Ling X. Survivin study: an update of “what is the next wave”? J Cell Physiol. 2006;208:476–86.
19. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis. 2007;28:1133–9.
20. Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. Cancer Sci. 2008;99:1709–14.
21. De Angelis PM, Stokke T, Thorstensen L, Lothe RA, Clausen OP. Apoptosis and expression of bax, bcl-x, and bcl-2 apoptotic regulatory proteins in colorectal carcinomas and association with p53 genotype/phenotype. Mol Pathol. 1998;51:254–61.
22. Maurer CA, Friess H, Bühler SS, Wahl BR, Graber H, Zimmermann A, Büchler MW. Apoptosis inhibiting factor Bcl-xL might be the crucial member of the Bcl-2 gene family in colorectal cancer. Dig Dis Sci. 1998;43:2641–8.
23. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Ierino H, Lee EF, Fairlie WD, Bouillet P, Strasser A, Kluck RM, Adams JM, Huang DC. Apoptosis is initiated when BH3 ligands engage multiple Bcl-2 homologs not Bax or Bak. Science. 2007;315:856–9.
24. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2:647–56.
25. Sinicrope FA, Rego RL, Foster NR, Thibodeau SN, Alberts SR, Windschitl HE, Sargent DJ. Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. Clin Cancer Res. 2008;14:4128–33.